Recent Progress in Stem Cell Therapy for Diabetic Nephropathy

Yang Liu    Sydney C.W. Tang

Division of Nephrology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, SAR, China

Key Words
Diabetic nephropathy · Stem cell therapy · Mesenchymal stem cells · Induced pluripotent stem cells

Abstract
Background: Diabetic nephropathy (DN) represents the leading cause of end-stage renal disease. Current therapeutic strategies for DN are very limited, and none of them can stop end-stage renal disease progression. Stem cell-based therapy showed encouraging outcomes in kidney disease, including experimental DN. Summary: Both podocytes and proximal tubular epithelial cells play key roles in the pathogenesis of DN and, accordingly, could be regarded as treatment targets. Multiple kinds of stem cells contribute to the regeneration of the injured kidney, including embryonic stem cells (ESCs), mesenchymal stem cells, and induced pluripotent stem cells (iPSCs). Stem cells exert reparatory effects mainly by homing to injured sites, directing differentiation, paracrine action, and immunoregulation. However, poor survival after transplantation under diabetic conditions and unsatisfactory animal models of advanced DN are major obstacles for achieving an efficacious therapeutic effect from stem cell transplantation. Recently, remarkable progress has been made both in the direct differentiation of human ESCs and iPSCs into renal cells and in the generation of tissue- and patient-specific iPSCs, offering a powerful tool to investigate DN mechanisms and to identify the ideal candidate cell for future clinical application. Key Message: This review provides updated information on recent progress and limitations of stem cell-based therapy for DN.

Introduction
Diabetes mellitus (DM) is one of the main threats to public health in developed countries. In 2013, more than 382 million people worldwide had DM [1], among which 90% were of type 2 DM [2]. It has been predicted that the number of people with DM will reach 439 million by 2030, affecting 7.7% of the world adult population aged 20–79 years [2]. In mainland China and Hong Kong, the estimated comparative prevalence of DM is 9.02 and 7.48%, respectively. Diabetic nephropathy (DN) is one of the most common detrimental complications of diabetes and represents the leading cause of end-stage renal disease [3]. About 25–40% of patients with diabetes will develop DN. To date, clinical interventions in the treatment of DN are very limited, and none of them can eliminate
the development of DN. The current treatment for DN includes full renin-angiotensin system blockade as well as stringent glycemic, lipid, and blood pressure control. However, the number of DN patients progressing to end-stage renal disease and requiring renal replacement therapy has continued to increase, and this imposes enormous medical and socioeconomic burdens [4]. Therefore, there is an urgent need for a regenerative strategy.

Stem cells have shown potential as a therapeutic strategy for DN. Stem cells are an undifferentiated population of cells, capable of self-renewal and differentiation towards one or more lineages to produce specialized cell types. Depending on their origin, stem cells are divided into embryonic stem cells (ESCs), adult stem cells, and induced pluripotent stem cells (iPSCs). In the past years, multiple types of cells have been used in preclinical animal models to repair or regenerate the diabetic kidney. This review summarizes recent progress in stem cell therapy for DN.

**Role of Podocytes and Tubular Cells in the Pathogenesis and Regeneration of DN**

**Role of Podocytes**

It is now widely recognized that podocytes play a central role in the pathogenesis of DN, which is clinically characterized by progressive proteinuria. Podocytes hold a strategic position and serve as key regulators of solute trafficking between the glomerular and tubulointerstitial compartments of the nephron. Injury to podocytes results in proteinuria and often leads to progression of fibrosis and irreversible renal dysfunction. In DN, podocytes are involved in the development of glomerular hypertrophy, podocyte hypertrophy, glomerulosclerosis, and foot process effacement [5]. Loss of podocytes is a hallmark of DN. The number of podocytes is decreased in the glomeruli of patients with type 1 or 2 diabetes, even in diabetics with a short duration of disease [6, 7]. High extracellular glucose can induce apoptosis in cultured podocytes via reactive oxygen species production and activation of pro-apoptotic p38 MAPK. In murine type 1 and type 2 diabetic models, apoptosis preceded podocyte depletion, urinary albumin excretion, and mesangial matrix expansion.

Unlike other fast renewing epithelial cells, podocytes have a slow turnover rate and a limited regeneration capacity. Once the podocyte is injured, the glomerular filtration barrier will become leaky, leading to proteinuria which further aggravates podocyte injury. Thus, podocyte injury is a major prognostic determinant in DN. Therefore, therapies aimed at preventing or limiting podocyte injury and/or at promoting podocyte repair or regeneration have major potential clinical and economic implications [8].

**Role of Proximal Tubular Epithelial Cells**

Emerging evidence suggests that proximal tubular epithelial cells (PTECs) play a pivotal role in the pathogenesis of DN [4]. Proteinuria, another hallmark of DN, is already known to activate PTECs to induce tubulointerstitial inflammation and fibrosis via a succession of intracellular events. In DN, tubulointerstitial injury appears early and closely correlates with renal function decline [9]. Infiltrating monocytes, macrophages, and T cells have been featured predominantly in the interstitium of diabetic kidney disease. We have previously defined tubuloglomerular and glomerulotubular crosstalk pathways [10] and interaction between protein-overloaded PTECs and infiltrating monocytes/T cells [11], supporting the important role of PTECs. In the diabetic milieu, exposure to high glucose, glycated albumin, and advanced glycosylated end product intermediates stimulates a pro-inflammatory and profibrotic phenotype in PTECs. Besides, targeted proximal tubule injury triggers interstitial fibrosis and glomerulosclerosis [12].

Chronic diabetic kidney disease is characterized by a reduced renal regenerative capacity [13], which is modulated by inflammation [14]. The link between inflammation and regeneration is the sharing of signaling pathways that regulate cell death cell cycle control. With the involvement of Bcl-2, transforming growth factor-β (TGF-β), tumor necrosis factor (TNF), Fas ligand, and interferon-α signal pathways, excessive apoptosis of normal glomerular and tubular epithelial cells disrupts the balance between cell proliferation and apoptosis in the early stage of DN, which eventually contributes to the progression of DN. Compared to podocytes, PTECs are believed to have a tremendous capacity for self-renewal. As the key determinant of the development of interstitial inflammation and fibrosis, PTECs might possess a higher potential to serve as an alternative key target in striving for a regenerative approach to DN treatment.

**Cell Sources for the Treatment of DN**

**Embryonic Stem Cells**

ESCs are pluripotent cells originating from the inner cell mass of the blastocyst [15], which can give rise to the three embryonic germ cell layers. Apart from the highest
differentiation potential into insulin secreting cells [16, 17], both mouse and human ESCs can be induced to differentiate toward a renal lineage by a panel of defined growth factors or inducers [18, 19]. By exposure to renal epithelial cell medium supplemented with Matrigel and a combination of defined low concentrations of bone morphogenetic protein-2 (BMP-2) and BMP-7, human ESCs were induced to differentiate into proximal tubular-like cells with expression of aquaporin-1 confirmed by immunofluorescence and fluorescence-activated cell sorting [19]. Under fully chemically defined monolayer culture conditions composed of BMP-4, activin A, FGF-7, and BMP-7, human ESCs differentiate through posterior primitive streak and intermediate mesoderm as normal nephrogenesis, and, subsequently, the ESC-derived kidney progenitors generate a self-organizing kidney after 3D culture [20]. Nevertheless, the concern of teratoma formation and ethical issues hamper the further clinical application potential of ESCs.

**Mesenchymal Stem Cells**

Mesenchymal stem cells (MSCs), also known as mesenchymal stromal cells, are a kind of adult stem cells [21]. Among stem cells, MSCs have several advantages for therapeutic use, such as ease of harvesting, multilineage differentiation potential, potent immunosuppressive effects, safety after infusion of allogeneic cells, and the lack of ethical issues that occur with the application of human ESCs. In the past decades, the therapeutic value of MSCs has been extensively assessed in a broad range of disease models and clinical trials.

MSCs can be isolated from numerous tissues, including bone marrow, adipose tissue [22], umbilical cord blood [23], peripheral blood [24], and amniotic fluid [25]. The richest source for MSCs is bone marrow. MSCs have been shown to differentiate into insulin-secreting cells [26], mesangial cells [27, 28], tubular epithelial cells [29], endothelial cells, and podocytes [30]. The safety and efficacy of allogeneic MSCs in treating acute kidney injury has been assessed in clinical trials and also in open-heart surgery patients who are at high risk of postoperative acute kidney injury [31, 32]. In preclinical studies, administration of MSCs has also shown potential to treat DN in several animal models. Injection of MSCs into streptozotocin (STZ)-induced type 1 diabetic mice improved renal and pancreatic function [33, 34]. In NOD/SCID mice, human MSCs decreased mesangial thickening and reduced macrophage infiltration [35]. In a type 1 DN rat model, administration of MSCs ameliorated proteinuria and podocyte injury [36]. Rats treated with MSCs showed a suppressed increase in kidney weight, kidney to body weight index, urinary albumin to creatinine ratio, and an increased creatinine clearance. Furthermore, the MSC treatment reduced the loss of podocytes, effacement of foot processes, widening of foot processes, thickening of the glomerular basal membrane, and loss of glomerular nephrin and podocin. Similar results were reported in rats which received intracardiac infusion of MSCs and cyclosporin [37].

Although MSCs have been widely applied in cell-based therapy, they still have some shortcomings. It has been reported that the MSC preparations from different laboratories or different donors are highly heterogeneous. Cell passage and culture conditions in vitro affect the phenotype of bone marrow MSCs. Furthermore, aging and aging-related disorders significantly impair the survival and differentiation potential of bone marrow MSCs [38–41]. Bone marrow MSCs isolated from chronic heart disease patients and chronic kidney disease rat models displayed a reduced proliferation and differentiation capacity [41–43], limiting their therapeutic efficacy.

**Urine-Derived Stem Cells**

Recently, researchers identified a subpopulation of cells isolated from urine that possesses biological characteristics similar to MSCs, namely urine-derived stem cells (USCs) [44, 45]. A major advantage of using USCs is that these cells can be obtained via a noninvasive, simple, safe, and low-cost procedure. With a higher telomerase activity and longer telomere length compared to other types of MSCs, USCs showed a high self-renewal and proliferation capacity. Upon induction with an appropriate culture condition, USCs can be differentiated into multiple cell lineages. Following implantation in vivo, USCs can form functional urothelial tissue [45]. For treatment of DN, the application of USCs is still at its infancy. Ouyang et al. [46] reported that human USCs genetically modified with fibroblast growth factor 2 (FGF2) relieved type 2 diabetic symptoms in a rat model. However, the role of USCs in the diabetic kidney remains unclear. Further studies need to be conducted.

**Induced Pluripotent Stem Cells**

The generation of iPSCs is a milestone in science. By the transduction of four defined transcription factors, namely Oct4, Sox2, Klf4, and c-Myc, terminally differentiated fibroblasts can be reprogrammed into pluripotent stem cells [47, 48]. The discovery of iPSCs was awarded the Nobel Prize in Medicine in 2012 only 6 years after its initial publication.
Like ESCs, iPSCs possess a great differentiation capacity. Recently, several promising protocols have been developed to directly differentiate human iPSCs into a renal fate [49–52]. By exposure to serum-free medium supple-
ment with retinoic acid, activin A, and BMP-2 for 4 days, human iPSCs and ESCs differentiated towards ureteric bud progenitor-like cells [49]. Lam et al. [50] reported a highly efficient system to induce human ESCs and iPSCs to differentiate into intermediate mesoderm that subsequently formed renal tubular cells. At the initial step, human iPSCs were induced to differentiate into BRACHYURY+MIXL1+ mesendoderm with nearly 100% efficiency by treatment with the glycogen synthase kinase-3b inhibitor CHIR99021. Then, PAX2+LHX1+ cells were generated with 70–80% efficiency followed by FGF2 and retinoic acid exposure. Upon growth factor withdrawal, these PAX2+LHX1+ cells formed tubular structures that coexpressed proximal tubule markers and kidney-specific protein and partially integrated into embryonic kidney explant cultures. Taguchi et al. [51] established a multi-step protocol to differentiate mouse ESCs and human iPSCs into a renal lineage by using a developmental strategy and lineage-tracing method. One study reported the differentiation of human iPSCs into podocyte-like cells [52]. The iPSC-derived cells shared a morphological phenotype analogous with cultured human podocytes following 10 days’ treatment with retinoic acid, activin A, and BMP-7 using a combination of embryonic body and monolayer culture condition, and emerging cytoplasmic projection-like foot processes. These cells expressed podocyte markers, including synaptopodin, nephrin, and Wilms tumor protein, but also maintained a proliferative capacity suggestive of a more immature phenotype.

To date, human iPSCs have been generated from multiple sources, including skin fibroblasts, keratinocytes, extraembryonic tissues, cord blood, and peripheral blood cells [47, 53–55]. Studies suggested that tissue-specific iPSCs retain the epigenetic pattern of the original parent cells. Song et al. [56] and Zhou et al. [57, 58] generated iPSCs from normal human kidney mesangial cells and exfoliated renal tubular cells present in urine of healthy donors, respectively, leading the way to developing a tissue-specific iPSC therapy for kidney disease [59]. Moreover, the general reprogramming efficiency from urine was higher than for other methods, between 0.1 and 4%. Apart from tissue-specific iPSCs, many kinds of disease-specific iPSCs have been produced, including type 1 diabetes [60, 61], autosomal-dominant polycystic kidney disease, autosomal-recessive polycystic kidney disease, Wilms tumor, and Alport syndrome [62–64]. The approach can also be applied for DN.

Most interestingly, combining the advantages of iPSCs and MSCs, Lian et al. [65] generated iPSC-derived MSCs (iPS-MSCs). iPS-MSCs can maintain a normal karyotype during culture expansion and constitutively express surface antigens of multipotent MSCs without any obvious loss of self-renewal capacity after 40 passages (120 population doublings). Moreover, like other cells generated from iPSCs [66], iPS-MSCs had a lower gene expression profile on T-cell activation and showed limited or no immune responses upon transplantation in an animal study, which is critical for clinical application. iPS-MSCs have shown therapeutic benefits in animal models of limb ischemia [65], allergic airway inflammation, and periodontitis [67, 68]. Recently, we established an adriamycin nephropathy model in NOD/SCID mice and found that treatment with iPS-MSCs significantly ameliorated renal dysfunction in adriamycin nephropathy mice. The therapeutic potential of iPS-MSCs for DN is worthy of further exploration.

**Major Therapeutic Mechanisms of Stem Cells**

**Homing and Direct Differentiation**

Although ESCs and iPSCs are more potent to differentiate into insulin-producing and renal cells in vitro, data on these cells are lacking in animal studies. In STZ-induced type 1 diabetes C57BL/6 mice transplanted with MSCs, evidence indicated that the engrafted MSCs homed to the pancreas and kidney, differentiated into insulin-producing cells in vivo, and prevented the newly generated β cells from being destroyed by the immune system [34]. In human MSC-treated NOD/SCID mice, there was an increase in pancreatic islets and β cells producing mouse insulin. Human Alu sequences in DNA were detected by PCR assays in the pancreas and kidney on day 17 or 32 after transplantation, but not in other tissues. A few of the human cells appeared to differentiate into glomerular endothelial cells in the glomeruli [35].

**Paracrine and Immunomodulation**

It may not be convincing that direct differentiation in vivo could be the dominating repair mechanism as, usually, only a small number of engrafted stem cells were detected in DN animal models. It has been well accepted that stem cells, especially MSCs, benefit the injured kidney mostly via paracrine action and immunomodulation in existing studies. MSCs have the ability to release a wide
range of trophic and immunomodulatory factors in vitro and in vivo, including vascular endothelial growth factor (VEGF), basic FGF, platelet-derived growth factor (PDGF), insulin-like growth factor-1, hepatocyte growth factor, and epidermal growth factor [69]. Hence, engrafted MSCs might modify the injured kidney by secreting these factors to trigger intracellular signaling in target cells or neighboring cells. We demonstrated that bone marrow MSCs modulate albumin-induced renal tubular inflammation and fibrosis by secreting hepatocyte growth factor and TNF-stimulated gene 6 (TSG-6) both in vitro and in vivo [70]. Conditioned medium of human umbilical cord blood-derived MSCs significantly inhibited α-SMA, TGF-β1, collagen I, and Hsp 47 upregulation and E-cadherin and BMP-7 downregulation induced by TGF-β1 in NRK-52E cells in a dose-dependent manner through secretion of humoral factors [71]. MSC-transplanted kidneys of type 1 diabetic rats expressed higher levels of BMP-7, indicating that the protective effects of MSCs may be mediated in part by increasing BMP-7 secretion [36]. Through the production of soluble factors, MSCs altered the secretion profile of dendritic cells, resulting in an increased production of the anti-inflammatory cytokine IL-10 and a decreased production of the proinflammatory factors IFN-γ and IL-12 [72]. Moreover, MSCs can suppress T-cell proliferation, inhibit proliferation and IgG secretion of B cells, influence dendritic cell maturation, and modulate other immune cells such as natural killer cells and macrophages [73, 74].

Limitations and Challenges

Stem Cells under Diabetic Conditions

The microenvironment under diabetic conditions is harsh for stem cells to survive, migrate to the target injured tissue, and exert their reparative functions. It has been found that a reduced synthesis of proteoglycans and glycosaminoglycans in the surrounding tissue results in a reduced proliferation and viability of MSCs in vivo [75]. Also, the production of advanced glycosylated end products inhibited the proliferation of MSCs by activating apoptosis and reactive oxygen species production [76]. In diabetic patients, oxidative stress may also influence the paracrine effects of MSCs under hypoxic conditions. In hypoxic MSCs, high glucose attenuates the production of angiogenic growth factors, including hypoxia-induced factor-1α, VEGF-A, and PDGF-B, by significantly increased intracellular superoxide levels in MSCs [76, 77]. In addition, the migratory capacity of MSCs is also impaired. Elevated osteoprotegerin in diabetic patients will neutralize the promigratory activity of TNF-related apoptosis-inducing ligand, which promotes the migration of bone marrow stem cells [78, 79]. Indeed, high glucose per se also directly reduces the migration of MSCs [78].

Animal Models of DN

The National Institute of Health-funded Animal Models of Diabetic Complications Consortium (AMDCC) published as guidelines the following three key criteria for an ideal rodent model of DN [80]: (1) greater than 50% decline in glomerular filtration rate during the lifetime of the animal; (2) albuminuria (10-fold increase compared with controls), and (3) characteristic pathologic changes including advanced mesangial matrix expansion, any degree of arteriolar hyalinosis, basement membrane thickening, and interstitial fibrosis. Unfortunately, the existing animal models of DN applied for stem cell treatment did not satisfy these criteria. Nonobese and STZ-induced diabetic animals only mimicked the earlier stages of human DN and infrequently developed features of human advanced DN [81]. The BTBR ob/ob mouse model of DN comes close to meeting all of the proposed criteria of the AMDCC and offers an alternative option in the future [82].

Conclusions and Future Prospects

Stem cell-based therapy holds promise for DN treatment. Although kidney-specific stem cells were identified in recent years, the involvement of these stem cells in the regeneration of the kidney was still in doubt [83]. Currently, each type of candidate cell for a cell-based approach has advantages and disadvantages. We need to continue seeking for better ideal cell sources or developing optimized manipulation methods of existing cells. No matter whether targeting podocytes, PTECs, or other cell types in DN, the ideal cell candidate for cell replacement should have the following properties. First, these cells should be easily accessible. Second, they should have a higher survival ability to weather the diabetic stress and the differentiation ability into the desired cell types both in vitro and in vivo. Last, but most crucial for clinical use, there is safety. Although significant advances have been made in generating iPSCs from somatic cells as well as functional kidney cells and tissues from pluripotent stem cells (ESCs and iPSCs), providing a wonderful platform to explore disease mechanisms and potential cell sources, the safety issue remains unsolved. Criteria for the validation of in-
duced renal progenitor cells need to be established. The tumorigenic property of iPSCs based on viral transduction technology must be eliminated before clinical transplantation. The development of iPSCs without viral vectors might be helpful in the generation of iPSCs from an autologous source [84]. Bone marrow MSCs remain an attractive autologous cell source mainly due to the ease of harvesting and their low immunogenicity. USCs or urine-derived iPSCs from DN patients might also serve as suitable cell sources for investigating the pathogenetic mechanisms, screening new treatment, and offering possibilities of future personalized regenerative therapies.

Acknowledgements

This study was supported by the National Basic Research Program of China 973, program No. 2012CB517600 (No. 2012CB517606), Health and Medical Research Fund of Food and Health Bureau (No. 02135258), Seed Funding Programme for Basic Research (No. 201411159105), Small Project Funding (No. 201309176123) from The University of Hong Kong, and Hong Kong Society of Nephrology Research Grant 2014.

Conflict of Interest Statement

The authors have no conflicts of interest to declare.

References


